Targeting intrinsically disordered proteins in rational drug discovery

Expert Opinion on Drug Discovery

Volumn 11, Issue 1, 2016, Pages 65-77

  Ambadipudi, Susmitha ^a   Zweckstetter, Markus ^a,b,c  

^a GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^b MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^c UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

drug discovery; intrinsically disordered protein; neurodegeneration; NMR spectroscopy

Indexed keywords

INTRINSICALLY DISORDERED PROTEIN; PROTEIN MDM2; PROTEIN P53;

ADENOSINE DIPHOSPHATE RIBOSYLATION; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ATOMIC FORCE MICROSCOPY; CARBOXY TERMINAL SEQUENCE; CIRCULAR DICHROISM; CONFORMATIONAL TRANSITION; CRYOELECTRON MICROSCOPY; DEGENERATIVE DISEASE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG TARGETING; HUMAN; HYDRODYNAMICS; MOLECULAR DYNAMICS; NERVE DEGENERATION; NONHUMAN; NUCLEAR OVERHAUSER EFFECT; POINT MUTATION; PRIORITY JOURNAL; PROTEIN ACETYLATION; PROTEIN AGGREGATION; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN FOLDING; PROTEIN GLYCOSYLATION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; PROTEIN TARGETING; RAMAN SPECTROMETRY; REVIEW; TRANSMISSION ELECTRON MICROSCOPY; UBIQUITINATION; X RAY CRYSTALLOGRAPHY; ANIMAL; CHEMICAL STRUCTURE; METABOLISM; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ANIMALS; DRUG DESIGN; DRUG DISCOVERY; HUMANS; INTRINSICALLY DISORDERED PROTEINS; MODELS, MOLECULAR; MOLECULAR TARGETED THERAPY; PROTEIN CONFORMATION;

EID: 84955194340     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2016.1107041     Document Type: Review

References (141)

1. Crick F. Central dogma of molecular biology. Nature. 1970;227 (5258):561-563.
2. Wright PE, Dyson HJ. Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J Mol Biol. 1999;293 (2):321-331.
3. Dunker AK, Obradovic Z. The protein trinity-linking function and disorder. Nat Biotechnol. 2001;19 (9):805-806.
4. Xue B, Dunbrack RL, Williams RW, et al. PONDR-FIT: A meta-predictor of intrinsically disordered amino acids. Biochim Biophys Acta. 2010;1804 (4):996-1010.
5. Wright PE, Dyson HJ. Intrinsically disordered proteins in cellular signalling and regulation. Nat Rev Mol Cell Bio. 2015;16 (1):18-29.
6. Rezaei-Ghaleh N, Blackledge M, Zweckstetter M. Intrinsically disordered proteins: from sequence and conformational properties toward drug discovery. Chembiochem. 2012;13 (7):930-950.
7. Jensen MR, Zweckstetter M, Huang JR, et al. Exploring free-energy landscapes of intrinsically disordered proteins at atomic resolution using NMR spectroscopy. Chem Rev. 2014;114 (13): 6632-6660.
8. Dyson HJ, Wright PE. Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Bio. 2005;6 (3):197-208.
9. Fisher CK, Stultz CM. Constructing ensembles for intrinsically disordered proteins. Curr Opin Struc Biol. 2011;21 (3):426-431.
10. Marsh JA, Teichmann SA, Forman-Kay JD. Probing the diverse landscape of protein flexibility and binding. Curr Opin Struc Biol. 2012;22 (5):643-650.
11. Mao AH, Lyle N, Pappu RV. Describing sequence-ensemble relationships for intrinsically disordered proteins. Biochem J. 2013;449 (2):307-318.
12. Dunker AK, Brown CJ, Lawson JD, et al. Intrinsic disorder and protein function. Biochemistry. 2002;41 (21):6573-6582.
13. Uversky VN. Natively unfolded proteins: A point where biology waits for physics. Prot Sci. 2002;11 (4):739-756.
14. Uversky VN, Dunker AK. Understanding protein non-folding. Biochim Biophys Acta. 2010;1804 (6):1231-1264.
15. Kovacs D, Szabo B, Pancsa R, et al. Intrinsically disordered proteins undergo and assist folding transitions in the proteome. Arch Biochem Biophys. 2013;531 (1-2):80-89.
16. Bah A, Vernon RM, Siddiqui Z, et al. Folding of an intrinsically disordered protein by phosphorylation as a regulatory switch. Nature. 2015;519 (7541):106-109.
17. Linding R, Jensen LJ, Diella F, et al. Protein disorder prediction: implications for structural proteomics. Structure. 2003;11 (11):1453-1459.
18. Ward JJ, Sodhi JS, McGuffin LJ, et al. Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. J Mol Biol. 2004;337 (3):635-645.
19. Pancsa R, Tompa P. Structural disorder in eukaryotes. PloS One. 2012;7 (4):e34687.
20. Theillet FX, Binolfi A, Frembgen-Kesner T, et al. Physicochemical properties of cells and their effects on intrinsically disordered proteins (IDPs). Chem Rev. 2014;114 (13):6661-6714.
21. Uversky VN, Dave V, Iakoucheva LM, et al. Pathological unfoldomics of uncontrolled chaos: intrinsically disordered proteins and human diseases. Chem Rev. 2014;114 (13):6844-6879.
22. Oldfield CJ, Cheng Y, Cortese MS, et al. Comparing and combining predictors of mostly disordered proteins. Biochemistry. 2005;44 (6):1989-2000.
23. Lobanov MY, Galzitskaya OV. How common is disorder? Occurrence of disordered residues in four domains of life. Int J Mol Sci. 2015;16 (8):19490-19507.
24. Prilusky J, Felder CE, Zeev-Ben-Mordehai T, et al. FoldIndex: A simple tool to predict whether a given protein sequence is intrinsically unfolded. Bioinformatics. 2005;21 (16):3435-3438.
25. Uversky VN, Oldfield CJ, Dunker AK. Intrinsically disordered proteins in human diseases: introducing the D2 concept. Annu Rev Biophys. 2008;37:215-246.
26. Sickmeier M, Hamilton JA, LeGall T, et al. DisProt: The database of disordered proteins. Nucleic Acids Res. 2007;35 (Database issue):D786-93.
27. Varadi M, Kosol S, Lebrun P, et al. pEDB: A database of structural ensembles of intrinsically disordered and of unfolded proteins. Nucleic Acids Res. 2014;42 (Database issue):D326-35.
28. Goedert M, Spillantini MG. A century of Alzheimer's disease. Science. 2006;314 (5800):777-781.
29. Romero PR, Zaidi S, Fang YY, et al. Alternative splicing in concert with protein intrinsic disorder enables increased functional diversity in multicellular organisms. P Natl Acad Sci USA. 2006;103 (22):8390-8395.
30. Hegyi H, Buday L, Tompa P. Intrinsic structural disorder confers cellular viability on oncogenic fusion proteins. PLoS Comput Biol. 2009;5 (10):e1000552.
31. Markiv A, Rambaruth ND, Dwek MV. Beyond the genome and proteome targeting protein modifications in cancer. Curr Opin Pharmacol. 2012;12 (4): 408-413.
32. Peng Z, Mizianty MJ, Xue B, et al. More than just tails: intrinsic disorder in histone proteins. Mol Biosyst. 2012;8 (7): 1886-1901.
33. Weatheritt RJ, Gibson TJ. Linear motifs: lost in (pre)translation. Trends Biochem Sci. 2012;37 (8):333-341.
34. Babu MM, van der Lee R, de Groot NS, et al. Intrinsically disordered proteins: regulation and disease. Curr Opin Struc Biol. 2011;21 (3):432-440.
35. Vendruscolo M. Enzymatic activity in disordered states of proteins. Curr Opin Chem Biol. 2010;14 (5):671-675.
36. Schulenburg C, Hilvert D. Protein conformational disorder and enzyme catalysis. Top Curr Chem. 2013;337:41-67.
37. Smock RG, Blackburn ME, Gierasch LM. Conserved, disordered C terminus of DnaK enhances cellular survival upon stress and DnaK in vitro chaperone activity. J Biol Chem. 2011;286 (36):31821-31829.
38. Tompa P, Csermely P. The role of structural disorder in the function of RNA and protein chaperones. FASEB J. 2004;18 (11):1169-1175.
39. Kuznetsova IM, Turoverov KK, Uversky VN. What macromolecular crowding can do to a protein. Int J Mol Sci. 2014;15 (12):23090-23140.
40. Greenwald J, Riek R. Biology of amyloid: structure, function, and regulation. Structure. 2010;18 (10):1244-1260.
41. Nag S, Sarkar B, Bandyopadhyay A, et al. Nature of the amyloid-beta monomer and the monomer-oligomer equilibrium. J Biol Chem. 2011;286 (16):13827-13833.
42. Chakrabortee S, Meersman F, Kaminski Schierle GS, et al. Catalytic and chaperone-like functions in an intrinsically disordered protein associated with desiccation tolerance. Proc Natl Acad Sci USA. 2010;107 (37):16084-16089.
43. Uversky VN. Targeting intrinsically disordered proteins in neurodegenerative and protein dysfunction diseases: Another illustration of the D (2) concept. Expert Rev Proteomics. 2010;7 (4):543-564.
44. Midic U, Oldfield CJ, Dunker AK, et al. Protein disorder in the human diseasome: unfoldomics of human genetic diseases. BMC Genomics. 2009;10 (Suppl 1):S12.
45. Uversky VN, Oldfield CJ, Midic U, et al. Unfoldomics of human diseases: linking protein intrinsic disorder with diseases. BMC Genomics. 2009;10 (Suppl 1):S7.
46. Hartl FU, Bracher A, Hayer-Hartl M. Molecular chaperones in protein folding and proteostasis. Nature. 2011;475 (7356):324-332.
47. Lee L, Sakurai M, Matsuzaki S, et al. SUMO and Alzheimer's disease. NeuroMolecular Med. 2013;15 (4): 720-736.
48. Uversky VN. Wrecked regulation of intrinsically disordered proteins in diseases: Pathogenicity of deregulated regulators. Front Mol Biosci. 2014;1:6.
49. Brown CJ, Lain S, Verma CS, et al. Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer. 2009;9 (12):862-873.
50. Muller PA, Vousden KH. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell. 2014;25 (3):304-317.
51. Collavin L, Lunardi A, Del Sal G. p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ. 2010;17 (6):901-911.
52. Nair SK, Burley SK. X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors. Cell. 2003;112 (2):193-205.
53. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. 1999;19 (1):1-11.
54. Hammoudeh DI, Follis AV, Prochownik EV, et al. Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc. J Am Chem Soc. 2009;131 (21):7390-7401.
55. Cheng Y, LeGall T, Oldfield CJ, et al. Rational drug design via intrinsically disordered protein. Trends Biotechnol. 2006;24 (10):435-442.
56. Abelev GI. Alpha-fetoprotein in ontogenesis and its association with malignant tumors. Adv Cancer Res. 1971;14:295-358.
57. Cooper GJ, Leighton B, Dimitriadis GD, et al. Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc Natl Acad Sci USA. 1988;85 (20):7763-7766.
58. Cheng Y, LeGall T, Oldfield CJ, et al. Abundance of intrinsic disorder in protein associated with cardiovascular disease. Biochemistry. 2006;45 (35):10448-10460.
59. Derisbourg M, Leghay C, Chiappetta G, et al. Role of the Tau N-terminal region in microtubule stabilization revealed by new endogenous truncated forms. Sci Rep. 2015;5:9659.
60. Chen J, Kanai Y, Cowan NJ, et al. Projection domains of MAP2 and tau determine spacings between microtubules in dendrites and axons. Nature. 1992;360 (6405):674-677.
61. Kadavath H, Hofele RV, Biernat J, et al. Tau stabilizes microtubules by binding at the interface between tubulin heterodimers. Proc Natl Acad Sci USA. 2015;112 (24):7501-7506.
62. Kadavath H, Jaremko M, Jaremko L, et al. Folding of the Tau protein on microtubules. Angew Chem. 2015;54 (35): 10347-10351.
63. Sergeant N, Bretteville A, Hamdane M, et al. Biochemistry of Tau in Alzheimer's disease and related neurological disorders. Expert Rev Proteomics. 2008;5 (2): 207-224.
64. Mandelkow EM, Biernat J, Drewes G, et al. Tau domains, phosphorylation, and interactions with microtubules. Neurobiol Aging. 1995;16 (3):355-362; discussion 62-3
65. Cripps D, Thomas SN, Jeng Y, et al. Alzheimer disease-specific conformation of hyperphosphorylated paired helical filament-Tau is polyubiquitinated through Lys-48, Lys-11, and Lys-6 ubiquitin conjugation. J Biol Chem. 2006;281 (16):10825-10838.
66. Cohen TJ, Guo JL, Hurtado DE, et al. The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun. 2011;2:252.
67. Buee L, Bussiere T, Buee-Scherrer V, et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000;33 (1): 95-130.
68. Tepper K, Biernat J, Kumar S, et al. Oligomer formation of tau protein hyperphosphorylated in cells. J Biol Chem. 2014;289 (49):34389-34407.
69. Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, et al. Tau oligomers as potential targets for immunotherapy for Alzheimer's disease and tauopathies. Curr Alzheimer Res. 2011;8 (6):659-665.
70. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121-1159.
71. Irwin DJ, Lee VM, Trojanowski JQ. Parkinson's disease dementia: convergence of alpha-synuclein, tau and amyloid-beta pathologies. Nat Rev Neurosci. 2013;14 (9):626-636.
72. Akoury E, Gajda M, Pickhardt M, et al. Inhibition of tau filament formation by conformational modulation. J Am Chem Soc. 2013;135 (7):2853-2862.
73. Noble W, Planel E, Zehr C, et al. Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci USA. 2005;102 (19):6990-6995.
74. Zhang B, Maiti A, Shively S, et al. Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model. Proc Natl Acad Sci USA. 2005;102 (1):227-231.
75. Pul R, Dodel R, Stangel M. Antibodybased therapy in Alzheimer's disease. Expert Opin Biol Ther. 2011;11 (3):343-357.
76. Davidson WS, Jonas A, Clayton DF, et al. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J Biol Chem. 1998;273 (16):9443-9449.
77. Auluck PK, Caraveo G, Lindquist S. alpha-Synuclein: membrane interactions and toxicity in Parkinson's disease. Annu Rev Cell Dev Biol. 2010;26:211-233.
78. Goedert M, Spillantini MG, Del Tredici K, et al. 100 years of Lewy pathology. Nat Rev Neurol. 2013;9 (1):13-24.
79. Jimenez JL, Guijarro JI, Orlova E, et al. Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO J. 1999;18 (4):815-821.
80. Wegmann S, Muller DJ, Mandelkow E. Investigating fibrillar aggregates of Tau protein by atomic force microscopy. Methods Mol Biol. 2012;849:169-183.
81. Gibbs EB, Showalter SA. Quantitative biophysical characterization of intrinsically disordered proteins. Biochemistry. 2015;54 (6):1314-1326.
82. Galea CA, Nourse A, Wang Y, et al. Role of intrinsic flexibility in signal transduction mediated by the cell cycle regulator, p27 Kip1. J Mol Biol. 2008;376 (3):827-838.
83. Ferreon AC, Moran CR, Gambin Y, et al. Single-molecule fluorescence studies of intrinsically disordered proteins. Methods Enzymol. 2010;472:179-204.
84. Ferreon AC, Moosa MM, Gambin Y, et al. Counteracting chemical chaperone effects on the single-molecule alpha-synuclein structural landscape. Proc Natl Acad Sci USA. 2012;109 (44):17826-17831.
85. Krishnan R, Goodman JL, Mukhopadhyay S, et al. Conserved features of intermediates in amyloid assembly determine their benign or toxic states. Proc Natl Acad Sci USA. 2012;109 (28):11172-11177.
86. Ferreon AC, Ferreon JC, Wright PE, et al. Modulation of allostery by protein intrinsic disorder. Nature. 2013;498 (7454):390-394.
87. Lee T, Moran-Gutierrez CR, Deniz AA. Probing protein disorder and complexity at single-molecule resolution. Semin Cell Dev Biol. 2015;37:26-34.
88. Ferreon AC, Gambin Y, Lemke EA, et al. Interplay of alpha-synuclein binding and conformational switching probed by single-molecule fluorescence. Proc Natl Acad Sci USA. 2009;106 (14):5645-5650.
89. Ferreon AC, Moran CR, Ferreon JC, et al. Alteration of the alpha-synuclein folding landscape by a mutation related to Parkinson's disease. Angew Chem. 2010;49 (20):3469-3472.
90. Aznauryan M, Nettels D, Holla A, et al. Single-molecule spectroscopy of cold denaturation and the temperature-induced collapse of unfolded proteins. J Am Chem Sci. 2013;135 (38):14040-14043.
91. Brucale M, Schuler B, Samori B. Singlemolecule studies of intrinsically disordered proteins. Chem Rev. 2014;114 (6):3281-3317.
92. Soranno A, Koenig I, Borgia MB, et al. Single-molecule spectroscopy reveals polymer effects of disordered proteins in crowded environments. Proc Natl Acad Sci USA. 2014;111 (13): 4874-4879.
93. Wuttke R, Hofmann H, Nettels D, et al. Temperature-dependent solvation modulates the dimensions of disordered proteins. Proc Natl Acad Sci USA. 2014;111 (14):5213-5218.
94. Konig I, Zarrine-Afsar A, Aznauryan M, et al. Single-molecule spectroscopy of protein conformational dynamics in live eukaryotic cells. Nat Methods. 2015;12 (8):773-779.
95. Bernado P, Svergun DI. Structural analysis of intrinsically disordered proteins by small-angle X-ray scattering. Mol Biosyst. 2012;8 (1):151-167.
96. Narayanan RL, Durr UH, Bibow S, et al. Automatic assignment of the intrinsically disordered protein Tau with 441-residues. J Am Chem Sci. 2010;132 (34): 11906-11907.
97. Felli IC, Pierattelli R. Recent progress in NMR spectroscopy: Toward the study of intrinsically disordered proteins of increasing size and complexity. IUBMB Life. 2012;64 (6):473-481.
98. Konrat R. NMR contributions to structural dynamics studies of intrinsically disordered proteins. J Magn Reson. 2014;241:74-85.
99. Yao X, Becker S, Zweckstetter M. A sixdimensional alpha proton detection-based APSY experiment for backbone assignment of intrinsically disordered proteins. J Biomol NMR. 2014;60 (4):231-240.
100. Wishart DS, Sykes BD. The 13C chemical-shift index: A simple method for the identification of protein secondary structure using 13C chemical-shift data. J Biomol NMR. 1994;4 (2):171-180.
101. Mittag T, Forman-Kay JD. Atomic-level characterization of disordered protein ensembles. Curr Opin Struc Biol. 2007;17 (1):3-14.
102. Jensen MR, Markwick PR, Meier S, et al. Quantitative determination of the conformational properties of partially folded and intrinsically disordered proteins using NMR dipolar couplings. Structure. 2009;17 (9):1169-1185.
103. Kosol S, Contreras-Martos S, Cedeno C, et al. Structural characterization of intrinsically disordered proteins by NMR spectroscopy. Molecules. 2013;18 (9):10802-10828.
104. Structural impact of Tau phosphorylation at threonine 231. Structure. 2015;23 (8):1448-1458.
105. Salmon L, Nodet G, Ozenne V, et al. NMR characterization of long-range order in intrinsically disordered proteins. J Am Chem Sci. 2010;132 (24):8407-8418.
106. Bertoncini CW, Jung YS, Fernandez CO, et al. Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc Natl Acad Sci. 2005;102 (5):1430-1435.
107. Dedmon MM, Lindorff-Larsen K, Christodoulou J, et al. Mapping longrange interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. J Am Chem Sci. 2005;127 (2):476-477.
108. Schwalbe M, Ozenne V, Bibow S, et al. Predictive atomic resolution descriptions of intrinsically disordered hTau40 and alphasynuclein in solution from NMR and small angle scattering. Structure. 2014;22 (2):238-249.
109. Mukrasch MD, Bibow S, Korukottu J, et al. Structural polymorphism of 441-residue tau at single residue resolution. PloS Biology. 2009;7 (2):e34.
110. Palmer AG, Massi F. Characterization of the dynamics of biomacromolecules using rotating-frame spin relaxation NMR spectroscopy. Chem Rev. 2006;106 (5):1700-1719.
111. Korzhnev DM, Kay LE. Probing invisible, low-populated states of protein molecules by relaxation dispersion NMR spectroscopy: An application to protein folding. Acc Chem Res. 2008;41 (3):442-451.
112. Allison JR, Varnai P, Dobson CM, et al. Determination of the free energy landscape of alpha-synuclein using spin label nuclear magnetic resonance measurements. J Am Chem Sci. 2009;131 (51):18314-18326.
113. Xiang S, Gapsys V, Kim HY, et al. Phosphorylation drives a dynamic switch in serine/arginine-rich proteins. Structure. 2013;21 (12):2162-2174.
114. Lindorff-Larsen K, Trbovic N, Maragakis P, et al. Structure and dynamics of an unfolded protein examined by molecular dynamics simulation. J Am Chem Sci. 2012;134 (8):3787-3791.
115. Piana S, Klepeis JL, Shaw DE. Assessing the accuracy of physical models used in protein-folding simulations: quantitative evidence from long molecular dynamics simulations. Curr Opin Struc Biol. 2014;24:98-105.
116. Patel S, Ramanujam V, Srivastava AK, et al. Conformational propensities and dynamics of a betagamma-crystallin, an intrinsically disordered protein. Phys Chem Chem Phys. 2014;16 (25):12703-12718.
117. Rezaei-Ghaleh N, Klama F, Munari F, et al. Predicting the rotational tumbling of dynamic multidomain proteins and supramolecular complexes. Angew Chem. 2013;52 (43):11410-11414.
118. Rezaei-Ghaleh N, Klama F, Munari F, et al. HYCUD: A computational tool for prediction of effective rotational correlation time in flexible proteins. Bioinformatics. 2015;31 (8):1319-1321.
119. Metallo SJ. Intrinsically disordered proteins are potential drug targets. Curr Opin Chem Biol. 2010;14 (4):481-488.
120. Follis AV, Hammoudeh DI, Wang H, et al. Structural rationale for the coupled binding and unfolding of the c-Myc oncoprotein by small molecules. Chem Biol. 2008;15 (11):1149-1155.
121. Cuchillo R, Michel J. Mechanisms of small-molecule binding to intrinsically disordered proteins. Biochem Soc Trans. 2012;40 (5):1004-1008.
122. Michel J, Cuchillo R. The impact of small molecule binding on the energy landscape of the intrinsically disordered protein C-myc. PloS One. 2012;7 (7):e41070.
123. Jin F, Yu C, Lai L, et al. Ligand clouds around protein clouds: A scenario of ligand binding with intrinsically disordered proteins. PLoS Comput Biol. 2013;9 (10): e1003249.
124. Krishnan N, Koveal D, Miller DH, et al. Targeting the disordered C terminus of PTP1B with an allosteric inhibitor. Nat Chem Biol. 2014;10 (7):558-566.
125. Heller GT, Sormanni P, Vendruscolo M. Targeting disordered proteins with small molecules using entropy. Trends Biochem Sci. 2015;40 (9):491-496.
126. Fonseca-Ornelas L, Eisbach SE, Paulat M, et al. Small molecule-mediated stabilization of vesicle-associated helical alphasynuclein inhibits pathogenic misfolding and aggregation. Nat Comm. 2014;5:5857.
127. Jung KY, Wang H, Teriete P, et al. Perturbation of the c-Myc-Max proteinprotein interaction via synthetic alphahelix mimetics. J Med Chem. 2015;58 (7):3002-3024.
128. Schirmer RH, Adler H, Pickhardt M, et al. Lest we forget you-methylene blue. Neurobiol Aging. 2011;32 (12):2325, e7-16.
129. Wischik CM, Staff RT, Wischik DJ, et al. Tau aggregation inhibitor therapy: An exploratory phase 2 study in mild or moderate Alzheimer's disease. J Alzheimers Dis. 2015;44 (2):705-720.
130. Akoury E, Pickhardt M, Gajda M, et al. Mechanistic basis of phenothiazine-driven inhibition of Tau aggregation. Angew Chem. 2013;52 (12):3511-3515.
131. Toth G, Gardai SJ, Zago W, et al. Targeting the intrinsically disordered structural ensemble of alpha-synuclein by small molecules as a potential therapeutic strategy for Parkinson's disease. PloS One. 2014;9 (2):e87133.
132. Weinreb PH, Zhen W, Poon AW, et al. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry. 1996;35 (43):13709-13715.
133. Acharya S, Safaie BM, Wongkongkathep P, et al. Molecular basis for preventing alpha-synuclein aggregation by a molecular tweezer. J Biol Chem. 2014;289 (15):10727-10737.
134. Prabhudesai S, Sinha S, Attar A, et al. A novel "molecular tweezer" inhibitor of alpha-synuclein neurotoxicity in vitro and in vivo. Neurotherapeutics. 2012;9 (2):464-476.
135. Mangialasche F, Solomon A, Winblad B, et al. Alzheimer's disease: clinical trials and drug development. Lancet Neurol. 2010;9 (7):702-716.
136. Chene P. Inhibition of the p53-MDM2 interaction: Targeting a protein-protein interface. Mol Cancer Res. 2004;2 (1): 20-28.
137. Khoo KH, Verma CS, Lane DP;. Drugging the p53 pathway: understanding the route to clinical efficacy. Nat Rev Drug Discov. 2014;13 (3):217-236.
138. Yin X, Giap C, Lazo JS, et al. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene. 2003;22 (40):6151-6159.
139. Aeluri M, Chamakuri S, Dasari B, et al. Small molecule modulators of protein-protein interactions: selected case studies. Chem Rev. 2014;114 (9): 4640-4694.
140. Belmar J, Fesik SW. Small molecule Mcl-1 inhibitors for the treatment of cancer. Pharmacol Ther. 2015; 145:76-84.
141. Besbes S, Mirshahi M, Pocard M, et al. New dimension in therapeutic targeting of BCL-2 family proteins. Oncotarget. 2015;6 (15):12862-12871.